drugset / Trial / NCT04717362

The Effects of Natesto For Treatment Of Hypogonadism

NCT04717362

Phase 0 Withdrawn Baylor College of Medicine
NaSingle-groupOpen-labelTreatment

Summary

In this prospective study, the investigators plan is to confirm the role of Natesto (intranasal testosterone) to combat hypogonadal symptoms in men trying to recover spermatogenesis following the withdrawal of conventional Testosterone replacement therapy.

Timeline

Start
2024-03-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 5.5 mg Intranasal